Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MacroGenics, Inc.

http://www.macrogenics.com/

Latest From MacroGenics, Inc.

FDA Perturbed By Provention's Teplizumab Type 1 Diabetes Drug

The US regulator is worried about deficiencies in the submission for Provention Bio’s high-profile therapy teplizumab for the prevention of type 1 diabetes that could significantly delay its review.

Metabolic Disorders Drug Review

BMS Jumps Ahead With LAG-3 Melanoma Data

LAG-3 antibody shows improved PFS when combined with Opdivo in metastatic or inoperable melanoma. Bristol Myers Squibb still awaits overall survival data but could have its second dual checkpoint inhibitor pairing.

Clinical Trials ImmunoOncology

Takeda Grows Immuno-Oncology Portfolio With $525m Maverick Acquisition

Maverick’s bispecific antibody program adds to Takeda’s expanding immuno-oncology development business, which also includes cell therapy programs.

Research & Development Research and Development Strategies

US FDA’s Three Review Speeds: Standard, Priority – And Oncology

FDA’s oncology review team likes to do things its own way – and at its own hyper fast pace.

Cancer Pink Sheet Perspectives
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Vaccines
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Raven Biotechnologies
UsernamePublicRestriction

Register